ArticleAJNR. American journal of neuroradiology2015
Intramedullary spinal cord metastases: prognostic value of MRI and clinical features from a 13-year institutional case series.
Article in AJNR. American journal of neuroradiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Intramedullary spinal cord metastasis from vaginal high-grade neuroendocrine carcinoma: A case report.Surgical neurology international · 2026Article
- Case Report: A case of diffuse midline glioma, H3 K27-altered presenting with long-segment spinal cord lesions.Frontiers in oncology · 2026Article
- Beyond surgical radicality in intramedullary spinal cord metastases: neurological function and systemic disease burden drive patient outcomes.Journal of neuro-oncology · 2025Article
- Spinal intramedullary uterine carcinosarcoma metastasis.BMJ case reports · 2024Article
- Intramedullary Spinal Cord Metastases from Differentiated Thyroid Cancer, a Case Report.Life (Basel, Switzerland) · 2022Article
- Clinical Features, Treatments, and Prognosis of Intramedullary Spinal Cord Metastases From Lung Cancer: A Case Series and Systematic Review.Neurospine · 2022Article
- Syphilitic meningomyelitis misdiagnosed as spinal cord tumor: Case and review.The journal of spinal cord medicine · 2021Article
- Image-Guided Robotic Radiosurgery for the Management of Intramedullary Spinal Cord Metastases-A Multicenter Experience.Cancers · 2021Article
- Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-MutantFrontiers in pharmacology · 2021Article
- Intramedullary spinal cord metastasis in malignancies: an institutional analysis and review.OncoTargets and therapy · 2019Article
- Metastatic Complications of Cancer Involving the Central and Peripheral Nervous Systems.Neurologic clinics · 2018Review
- Palliative Radiation Therapy for Intramedullary Spinal Cord Metastasis.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeIn patients with intramedullary spinal cord metastases, the impact of MR imaging and clinical characteristics on survival has not been elucidated. Our aim was to identify MR imaging and clinical features with prognostic value among patients with intramedullary spinal cord metastases from a large retrospective series. MATERIALS AND
methodsThe relevant MR imaging examination and baseline clinical data for each patient from a consecutive group of patients with intramedullary spinal cord metastases had previously been reviewed by 2 neuroradiologists. Additional relevant clinical data were extracted. The influence of clinical and imaging characteristics on survival was assessed by Kaplan-Meier survival curves and log-rank tests for categoric characteristics.
resultsForty-nine patients had 70 intramedullary spinal cord metastases; 10 (20%) of these patients had multiple metastases. From the date of diagnosis, median survival for all patients was 104 days (95% CI, 48-156 days). One clinical feature was associated with decreased median survival: lung or breast primary malignancy (57 days) compared with all other malignancy types (308 days; P < .001). Three MR imaging features were associated with decreased median survival: multiple intramedullary spinal cord metastases (53 versus 121 days, P = .022), greater longitudinal extent of cord T2 hyperintensity (if ≥3 segments, 111 days; if ≤2, 184 days; P = .018), and ancillary visualization of the primary tumor and/or non-CNS metastases (96 versus 316 days, P = .012).
conclusionsSpinal cord edema spanning multiple segments, the presence of multifocal intramedullary spinal cord metastases, and ancillary evidence for non-CNS metastases and/or the primary tumor are MR imaging features associated with decreased survival and should be specifically sought. Patients with either a lung or breast primary malignancy are expected to have decreased survival compared with other primary tumor types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.